Clinical Characteristics and Outcomes of Influenza A Infection in Kidney Transplant Recipients: A Single-Center Experience

Transplantation Proceedings

Volumn 48, Issue 7, 2016, Pages 2315-2318

  Odongo, F C A ^a   Azevedo, L S ^a   Neto, E D ^a   Yeh Li, H ^a   Caiaffa, H ^a   Pierrotti, L C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BACTERIAL PNEUMONIA; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL OUTCOME; COHORT ANALYSIS; FEMALE; GRAFT RECIPIENT; HOSPITAL ADMISSION; HUMAN; INCIDENCE; INFLUENZA A; INTENSIVE CARE UNIT; KIDNEY TRANSPLANTATION; MALE; MORTALITY RATE; OUTCOME ASSESSMENT; PERSONAL EXPERIENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; AGED; BRAZIL; COINFECTION; COUGHING; DYSPNEA; FEVER; GRAFT REJECTION; HOSPITALIZATION; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; INFLUENZA A VIRUS; INFLUENZA A VIRUS (H1N1); INFLUENZA, HUMAN; MIDDLE AGED; MORTALITY; MYALGIA; PNEUMONIA, BACTERIAL; RISK FACTOR; STATISTICS AND NUMERICAL DATA; TIME FACTOR; UTILIZATION; YOUNG ADULT;

IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; BRAZIL; COINFECTION; COUGH; DYSPNEA; FEMALE; FEVER; GRAFT REJECTION; HOSPITALIZATION; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; INTENSIVE CARE UNITS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYALGIA; PNEUMONIA, BACTERIAL; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TRANSPLANT RECIPIENTS; YOUNG ADULT;

EID: 84992364660     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2016.06.024     Document Type: Article

References (22)

1. [1] World Health Organization. Influenza virus infections in humans. February 2014 Available at: http://www.who.int/influenza/human_animal_interface/virology_laboratories_and_vaccines/influenza_virus_infections_humans_feb14.pdf Accessed December 14, 2015.
2. [2] Viasus, D., Pano-Pardo, J.R., Pachón, J., et al. Factors associated with severe disease in hospitalized adults with pandemic (H1N1) 2009 in Spain. Clin Microbiol Infect 17 (2011), 738–746.
3. [3] Kumar, D., Michaels, M.G., Morris, M.I., et al. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect Dis 10 (2010), 521–526.
4. [4] Vilchez, R.A., McCurry, K., Dauber, J., et al. S. Influenza virus infection in adult solid organ transplant recipients. Am J Transplant 2 (2002), 287–291.
5. [5] Nichols, W.G., Guthrie, K.A., Corey, L., Boeckh, M., Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis 39 (2004), 1300–1306.
6. [6] Memoli, M.J., Athota, R., Reed, S., et al. The natural history of influenza infection in the severely immunocompromised vs immunocompromised hosts. Clin Infect Dis 58 (2014), 214–224.
7. [7] Briggs, J.D., Timbury, M.C., Paton, A.M., et al. Viral infection and transplant rejection. BMJ, 4, 1972, 520.
8. [8] Katerinis, I., Hadaya, K., Duquesnoy, R., et al. De novo anti-HLA antibody after pandemic H1N1 and seasonal influenza immunization in kidney transplant recipients. Am J Transplant 11 (2011), 1727–1733.
9. [9] Low, C.Y., Kee, T., Chan, K.P., et al. Pandemic (H1N1) 2009 infections in adult solid organ transplant recipients in Singapore. Transplantation 90 (2010), 1016–1020.
10. [10] Cordero, E., Perez-Romero, P., Moreno, A., et al. Pandemic influenza A (H1N1) virus infection in solid organ transplant recipients: impact of viral and nonviral co-infection. Clin Microbiol Infect 18 (2012), 67–73.
11. [11] Liao, Y.C., Hsieh, Y.C., Chang, W.C., et al. Fulminant myocarditis in an adult with 2009 pandemic influenza A (H1N1 influenza) infection. J Chin Med Assoc 74 (2011), 130–133.
12. [12] Asadi-Pooya, A.A., Yaghoubi, E., Nikseresht, A., et al. The neurological manifestations of H1N1 influenza infection; diagnostic challenges and recommendations. Iran J Med Soc 36 (2011), 36–39.
13. [13] Treanor, J.J., Hayden, F.D., Vrooman, S.P., et al. Efficacy and safety of the neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA 283 (2000), 1016–1024.
14. [14] Kumar, D., Morris, M.I., Kotton, S.N., et al. Guidance on novel influenza A/H1N1 in solid organ transplant recipients. Am J Transplant 10 (2010), 18–25.
15. [15] Aoki, F.Y., Macleod, M.D., Paggiaro, P., et al. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother 51 (2003), 123–129.
16. [16] Zapata, R., Uribe, M., Martínez, W., et al. Severe novel H1N1 influenza A infection in the immediate postoperative period of a liver transplant patient. Liver Transpl 16 (2010), 447–452.
17. [17] Danziger-Isakov, L., Kumar, D., AST Infectious Diseases Community of Practice. Vaccination in solid organ transplantation. Am J Transplant 13 (2013), 311–317.
18. [18] Miraglia, J.L., Abdala, E., Hoff, P.M., et al. Immunogenicity and reactogenicity of 2009 influenza A(H1N1)pdm09 inactivated monovalent nonadjuvanted vaccine in elderly and immunocompromised patients. PLoS One, 6, 2011, e27214.
19. [19] Azevedo, L.S., Gerhard, J., Miraglia, J.L., et al. Seroconversion of 2009 pandemic influenza A(H1N1)pdm09 vaccination in kidney transplant patients and the influence of different risk factors. Transpl Infect Dis 15 (2013), 612–618.
20. [20] Fairhead, T., Hendren, E., Tinckam, K., et al. Poor seroprotection but allosensitization after adjuvanted pandemic influenza H1N1 vaccine in kidney transplant recipients. Transpl Infect Dis 14 (2012), 575–583.
21. [21] Smith, K.G.C., Isbel, N.M., Catton, M.G., et al. Suppression of the humoral immune response by mycophenolate mofetil. Nephrol Dial Transplant 13 (1998), 160–164.
22. [22] Freitas, T.V.S., Ono, G., Correa, L., et al. Clinical manifestations and evolution of infection by influenza A (H1N1) in kidney transplant recipients. J Bras Nefrol 33 (2011), 136–141.